zunsemetinib
zunsemetinib: developed by 1 company · 2 clinical trials tracked.
zunsemetinib evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could zunsemetinib → ACRS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | Phase 2 |
Clinical Trials (2)
Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Primary endpoint: Recommended phase II dose (RP2D) of zunsemetinib in combination with mFOLFIRINOX (Dose Escalation Only)
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Primary endpoint: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12
Frequently asked questions
Who is developing zunsemetinib?
zunsemetinib is being developed by Aclaris Therapeutics, Inc..
How many clinical trials involve zunsemetinib?
BioSniper tracks 2 clinical trials involving zunsemetinib.